Medicus Pharma submits optimized Phase 2 study design for Teverelix

Quantum Helium Limited CEO Howard Mclaughlin joined Steve Darling from Proactive to announce that the company has received approval from the Bureau of Indian Affairs to assume operatorship of the Sagebrush Project in Colorado, marking a key milestone in its development strategy. McLaughlin explained that Quantum holds prospective helium resources of more than 1 billion cubic feet across its Sagebrush and Coyote Wash projects, providing a strong foundation for future growth. He noted that the operatorship approval follows an extensive and proactive engagement process with regulatory authorities and stakeholders. A recent company visit to Colorado, including meetings with the Ute Mountain Ute Tribe and relevant regulators, contributed positively to advancing and finalizing the approvals process. With operatorship now secured, Quantum is moving into the next operational phase at Sagebrush, with mobilization for an extended production test at the Sagebrush-1 well expected to begin shortly. The test, which is expected to run over several weeks, represents a key near-term milestone. Historically, the well encountered non-combustible gas with helium concentrations of approximately 2.76%, providing strong technical validation of the helium potential within the Leadville Formation. The upcoming program is designed to evaluate flow rates and confirm commercial deliverability. Importantly, results from the extended production test are expected to support the conversion of existing helium resources into reserves, a critical step toward commercial development of the project. The company has already completed extensive planning and procurement of long-lead equipment, positioning it to move efficiently into the testing phase following receipt of operatorship approval. #proactiveinvestors #QuantumHeliumLimited #aim #qhe #helium #HeliumExploration #SagebrushProject #ColoradoEnergy #HeliumResources #EnergyDevelopment #Operatorship #ResourceEstimates #ProductionTesting #OilAndGas #CleanEnergy #CriticalResources #ProjectDevelopment #EnergyMarkets #ExplorationUpdate

Bit Digital CEO Sam Tabar joined Steve Darling from Proactive to discuss the company’s 2025 financial results, its strategic shift away from Bitcoin mining, and its growing focus on Ethereum staking and AI infrastructure. The company reported approximately $115 million in revenue for 2025, reflecting a deliberate transformation of its business model. Tabar explained that Bit Digital Inc has been reallocating capital away from Bitcoin mining into higher-return opportunities, particularly Ethereum staking and high-performance computing (HPC). Ethereum has emerged as a core pillar of the company’s strategy, with holdings reaching approximately 155,000 ETH. The majority of these holdings are staked to generate yield, contributing to a significant increase in staking revenue. Tabar noted that “staking revenue actually increased by 300% this year,” highlighting the rapid expansion of this segment and its growing importance to overall performance. The company views Ethereum as programmable financial infrastructure, enabling both yield generation and deeper participation in network economics. Bit Digital is also expanding its exposure to AI infrastructure through its majority stake in WhiteFiber, while maintaining a disciplined approach to capital allocation. The company is actively evaluating acquisition opportunities aimed at building cash-generating businesses and establishing a long-term growth flywheel. Tabar emphasized that the company’s exit from Bitcoin mining is permanent, citing declining economics and capital inefficiencies across the sector as key drivers behind the decision. #proactiveinvestors #bitdigitalinc #nasdaq #btbt #Ethereum #ETHStaking #AIInfrastructure #HighPerformanceComputing #CryptoStrategy #DigitalAssets #Blockchain #StakingRewards #TechTransformation #WhiteFiber #AIGrowth #CloudComputing #CryptoMining #FinancialResults

BlockchaAIn Digital Infrastructure, COO Eyal Rozen joined Steve Darling from Proactive to discuss the company’s strategic shift toward AI-focused data centers and its recent listing on the NYSE American. Rozen explained that the company, originally founded in 2022 with a focus on Bitcoin mining, has rapidly evolved to meet surging demand for AI infrastructure. Recognizing early that AI workloads would become a dominant driver of data center demand, the company transitioned away from a pure mining model toward hosting AI colocation customers. Today, approximately 80–90% of BlockchaAIn’s resources are dedicated to AI infrastructure, positioning the company to capitalize on one of the fastest-growing segments in the digital economy. Rozen emphasized the critical role of energy availability in this shift, noting that “power is king” as companies compete to secure capacity for AI operations. In response, BlockchaAIn is actively acquiring and repurposing data centers across the United States, including a recent 20-megawatt project for a major undisclosed client. This strategy includes converting legacy Bitcoin mining facilities into AI-ready infrastructure. The company is currently expanding its footprint across key U.S. regions, including the southern states and Minnesota, while simultaneously evaluating multiple acquisition opportunities. Rozen added that the U.S. remains BlockchaAIn’s primary market due to its scale and strong demand dynamics. Looking ahead, the company plans to secure additional land and power resources, align customer demand with operational readiness, and raise further capital to support continued growth following its public listing. #proactiveinvestors #BlockchaAIn #nyseamerican #aib #AIInfrastructure #DataCenters #ArtificialIntelligence #DigitalInfrastructure #NYSEAmerican #AIGrowth #Colocation #BitcoinMining #EnergyDemand #CloudComputing #TechInfrastructure #DataCenterGrowth #AIRevolution #InfrastructureInvestment

Immunic Inc (NASDAQ:IMUX, FRA:10VA) chief operating officer Jason Tardio talked with Proactive's Stephen Gunnion about the importance of science-led innovation in tackling neurological diseases, particularly multiple sclerosis, on World Health Day 2026. Tardio highlighted that the biotech industry is fundamentally grounded in scientific research and data, noting that “everything we do is rooted in science.” He explained that Immunic is focused on developing innovative therapies designed to improve patient outcomes and address significant unmet medical needs. The discussion centred on multiple sclerosis (MS), a complex neurological disease that continues to present challenges despite decades of progress. Tardio pointed out that while advancements have been made, “the disease is not solved for,” with many patients still experiencing disability progression and requiring safer, more tolerable treatments. He emphasised the urgent need for innovation, particularly in progressive forms of MS where treatment options remain extremely limited. Immunic’s lead asset, vidofludimus calcium, is being developed as a novel approach aimed at addressing the full spectrum of the disease. Tardio also reinforced the broader mission of the healthcare and biotech sectors, stating that the ultimate goal is to help individuals “live a better quality of life” and “a healthier life longer.” Watch the full interview to learn more about Immunic’s approach to advancing MS treatment through science. For more videos like this, visit Proactive's YouTube channel, like this video, subscribe to the channel, and enable notifications so you never miss an update. #Immunic #MultipleSclerosis #BiotechInnovation #Healthcare #MSResearch #DrugDevelopment #ClinicalTrials #Neurology #WorldHealthDay #ScienceDriven #VidofludimusCalcium #PharmaNews #BiotechNews

Gelion PLC (AIM:GELN) chief technology officer Louis Adriaenssens joined Proactive's Stephen Gunnion to explain why the company's expanded collaboration with TDK Corporation could be a defining moment for its NES cathode technology. Adriaenssens revealed how Gelion has successfully transferred its technology into a pouch cell format, a critical step on the road to commercialisation, and why its cathode works seamlessly with standard lithium-ion components already used in mass manufacturing. With TDK dominant in the drone battery market and a major force in consumer electronics, this partnership is more than a vote of confidence. It's a potential launchpad into automotive, electronics and beyond — ultimately scaling to gigawatt-hour production levels. Prototype results are coming. Find out why they could be the catalyst that changes everything. For more videos like this, visit Proactive’s YouTube channel, like this video, subscribe to the channel, and enable notifications so you never miss an update. #Gelion #BatteryTechnology #EnergyStorage #TDK #DroneTechnology #LithiumIon #CleanTech #BatteryInnovation #EVBatteries #TechInvesting #EnergyTransition #ProactiveInvestors

One Bullion CEO Adam Berk joined Steve Darling from Proactive to discuss the company’s rapid growth following its recent public listing and its expanding gold exploration footprint across Africa. Berk explained that One Bullion Ltd has quickly established a strong presence, controlling more than 5,000 square kilometres across three key projects: Vumba, Maitengwe, and Kraaipan. He emphasized the strength of the company’s operating region, describing it as one of Africa’s most attractive mining jurisdictions—politically stable, transparent, and largely underexplored—offering significant upside potential for discovery. Vumba stands out as the company’s flagship asset, already supported by legacy drilling and ongoing artisanal mining activity. One Bullion plans to initiate geophysical surveys within the next 60 days, followed by a targeted drill program exceeding $1 million later this year. Maitengwe is expected to follow with exploration activity in the third quarter, while Kraaipan represents a longer-term “blue sky” opportunity. The project hosts 48 identified targets, with exploration programs planned through 2027. Berk also highlighted strong corporate momentum, including the completion of a reverse takeover (RTO), a $5 million capital raise, and growing institutional participation. He added that 2026 is shaping up to be a transformative year as the company advances multiple projects in parallel. #proactiveinvestors #onebullion #GoldExploration #AfricaMining #MiningGrowth #VumbaProject #Maitengwe #Kraaipan #GoldDiscovery #MineralExploration #Geophysics #DrillingProgram #MiningInvestment #ResourceDevelopment #JuniorMining #ExplorationUpdate

Medicus Pharma Chief Medical Officer Dr Faisal Mehmud joined Steve Darling from Proactive to announce that the company has submitted an optimized Phase 2 clinical study design to the U.S. Food and Drug Administration for Teverelix. The therapy is being developed to help prevent recurrent acute urinary retention (AUR) in men with benign prostatic hyperplasia (BPH) under the company’s existing open Investigational New Drug application. Mehmud explained that the updated study design has been refined under the leadership of Steven A. Kaplan, MD, FACS, a globally recognized expert in urology and men’s health, who will serve as Principal Investigator. He noted that there are currently no approved pharmacological therapies specifically indicated to prevent the recurrence of AUR, which is most caused by an enlarged prostate. Medicus Pharma’s proof-of-concept approach for Teverelix aims to address this unmet need, targeting a market estimated at approximately $2 billion. The revised Phase 2 study design, known as ANT-2111-02, includes a targeted sample size of approximately 126 patients across sites in the United States and Europe. The study is designed to detect a clear pharmacodynamic signal, specifically total prostate volume reduction, within an expected timeframe of about 12 weeks. The optimized design reflects a data-driven approach, reducing the study size by roughly threefold compared to the original plan. This adjustment is expected to significantly lower development costs while improving efficiency and execution speed. The streamlined approach also positions the company for earlier strategic engagement and potential partnering discussions. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #ClinicalTrials #Phase2 #Teverelix #Biotech #DrugDevelopment #FDA #Urology #BPH #AUR #MensHealth #PharmaInnovation #Healthcare #MedicalResearch #Biopharma

American Rare Earths CEO Mark Wall joined Steve Darling from Proactive to announce rapid progress on the company’s pilot plant program aimed at producing pre-production rare earth concentrate from Halleck Creek ore. As part of this advancement, the company has engaged Jaye T. Pickarts, P.E. to lead the pilot plant process, bringing extensive U.S.-based rare earth and project development expertise to this critical stage. Wall explained that Pickarts is a metallurgical engineer and Registered Professional Engineer with more than four decades of experience in mine development, mineral processing, and environmental compliance. His background includes leadership roles in rare earth demonstration plants and Wyoming-based permitting and operations. In previous positions, including a senior role at engineering firm Knight Piésold, Pickarts oversaw the design, construction, and commissioning of rare earth pilot and demonstration facilities. He has also contributed to multiple technical studies, advancing projects from early scoping through to feasibility. His combined expertise in flowsheet development and plant execution will be instrumental in integrating and de-risking the Halleck Creek pilot circuit. To support the program, American Rare Earths has ordered three key pieces of front-end processing equipment. The company has already received two Induced Roll Magnetic Separators (IRMS) manufactured by Mineral Technologies, headquartered in Starke, Florida. In addition, it has ordered a “GradePro” Reflux Classifier from FLSmidth in Salt Lake City, Utah, which is currently being fabricated on an expedited schedule. The remainder of the circuit will utilize standard, well-established processing equipment, allowing the team to focus on efficiently integrating and optimizing these critical components. The company has also announced it has brought on t Tetra Tech, a U.S. based major consulting and engineering services company, to complete an Oxides to Metals study for the Company’s heavy rare earths stream. The study will evaluate options to convert separated heavy rare earth oxides from the American Rare Earths Halleck Creek Project in Wyoming all the way to metal, a critical midstream step immediately preceding the manufacture of permanent magnets relied upon by defense and advanced technology sectors. #proactiveinvestors #americanrareearthslimited #asx #arr #otcqx #arrnf #adr #amrry #wyomingrareinc #RareEarths #HalleckCreek #PilotPlant #MineralProcessing #CriticalMinerals #Metallurgy #MiningInnovation #TREO #ResourceDevelopment #WyomingMining #ProcessEngineering #CleanTech #SupplyChain #ProjectDevelopment

Valereum PLC (AQSE:VLRM, FRA:6TJ, OTCQB:VLRMF) CEO Gary Cottle talked with Proactive about the launch of VGOLD, a new product aiming to differentiate itself in the growing tokenised gold market by offering yield alongside digital gold exposure. Cottle explained that VGOLD stands out as “probably the only gold token that will pay a yield or a coupon,” adding that investors who stake tokens for longer than a year could see returns between 10% and 15%. This positions VGOLD as both a store of value and an income-generating digital asset. The discussion also covered liquidity and flexibility. Cottle noted that VGOLD and its associated VGOLD-CORE tokens are designed to be “very liquid,” with the ability to convert into cash, tether gold, and other assets. This flexibility allows Valereum to actively manage and deploy capital while maintaining exposure to gold-linked instruments. Part of the strategy includes transitioning existing bond assets into VGOLD-CORE, described as a liquidity pool, subject to verification processes for underlying assets. The company expects this to enhance both returns and usability. Cottle also highlighted the importance of Valereum’s collaboration with Quorium Global Photonics (QGP), describing the partnership as fundamental to building the VGOLD ecosystem. The alignment includes shared technology, revenue opportunities, and complementary asset pipelines. Looking ahead, a potential US listing remains a key objective, though dependent on achieving stable revenues. With multiple deals in progress across gold and real estate tokenisation, VGOLD is seen as a primary driver toward near-term revenue generation. For more insights like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #Valereum #VGOLD #TokenizedGold #GoldInvestment #CryptoAssets #DigitalGold #BlockchainFinance #YieldInvesting #Fintech #RealWorldAssets #RWA #CryptoNews #Investing #GoldTokens #Web3Finance

Abingdon Health PLC (AIM:ABDX) executive chairman Dr Chris Hand talked with Proactive's Stephen Gunnion about the company’s strong first-half performance, recent contract wins and growth outlook in the diagnostics market. Hand explained that Abingdon Health operates as a contract development and manufacturing organisation specialising in lateral flow and rapid diagnostic testing, now offering a full-service, end-to-end solution from product development through to regulatory approval and manufacturing. This expanded “one-stop shop” model is helping differentiate the company in a competitive sector. The company reported a 45% increase in revenue in the first half, with expectations for an even stronger second half. Hand also highlighted two major contract wins, including a $2.5 million international project and a £4.8 million agreement to develop multiplex lateral flow tests. These tests allow multiple biomarkers to be analysed in a single device, moving beyond traditional yes/no diagnostics. As Hand noted, “these tests [are] basically an onsite version of a lab test,” reflecting growing demand from biotech and pharmaceutical customers. The company is also expanding its US presence, with its Madison, Wisconsin, facility supporting increased manufacturing capacity and trading of its shares on the OTCQB to improve investor access and liquidity. Looking ahead, continued contract momentum and revenue growth are expected to drive performance through the second half of the year. For more videos like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #AbingdonHealth #Diagnostics #LateralFlow #Biotech #HealthcareInnovation #RapidTesting #MedTech #Pharma #InvestorNews #SmallCaps #AIMMarket #USExpansion #MultiplexTesting #GrowthStocks